Short Interest in Affimed (NASDAQ:AFMD) Grows By 194.3%

Affimed (NASDAQ:AFMD) was the target of a large increase in short interest in June. As of June 15th, there was short interest totalling 921,900 shares, an increase of 194.3% from the May 31st total of 313,200 shares. Currently, 7.1% of the company’s stock are short sold. Based on an average trading volume of 674,600 shares, the days-to-cover ratio is presently 1.4 days.

Analyst Ratings Changes

Several research firms recently weighed in on AFMD. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Affimed in a report on Thursday, June 13th. Cantor Fitzgerald restated an “overweight” rating on shares of Affimed in a research note on Monday, April 1st. Wells Fargo & Company decreased their price target on Affimed from $30.00 to $25.00 and set an “overweight” rating for the company in a research report on Monday, April 1st. Finally, Laidlaw upped their price objective on Affimed from $15.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, June 13th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, Affimed currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.67.

Affimed Stock Down 1.8 %

Affimed stock traded down $0.10 during midday trading on Thursday, hitting $5.47. 68,701 shares of the company’s stock were exchanged, compared to its average volume of 399,959. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.06 and a quick ratio of 3.06. The stock has a 50-day moving average price of $5.49 and a two-hundred day moving average price of $5.50. Affimed has a 52-week low of $2.23 and a 52-week high of $8.95.

Institutional Trading of Affimed

Hedge funds have recently added to or reduced their stakes in the business. EWA LLC bought a new position in shares of Affimed during the fourth quarter valued at about $89,000. abrdn plc bought a new position in Affimed during the 4th quarter worth approximately $130,000. Vestal Point Capital LP bought a new position in shares of Affimed in the fourth quarter worth approximately $341,000. Finally, BNP Paribas Financial Markets increased its stake in shares of Affimed by 39.9% in the fourth quarter. BNP Paribas Financial Markets now owns 571,975 shares of the biopharmaceutical company’s stock worth $357,000 after buying an additional 163,162 shares during the period. 30.82% of the stock is owned by institutional investors.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.